Publications by authors named "D Randal Kipp"

Claim this Profile
T
The PINNACLE study: A multicentre phase II trial of nilotinib in combination with pegylated interferon-α2b in newly diagnosed chronic phase chronic myeloid leukaemia.
David T Yeung, Andrew P Grigg, John Reynolds, Susan Branford, Deepmala Mazumdar, David Kipp

Br J Haematol· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
How comparable are patient outcomes in the "real-world" with populations studied in pivotal AML trials?
Ing Soo Tiong, Meaghan Wall, Ashish Bajel, Akash Kalro, Shaun Fleming, David Kipp

Blood Cancer J· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery and Clinical Proof-of-Concept of RLY-2608, a First-in-Class Mutant-Selective Allosteric PI3Kα Inhibitor That Decouples Antitumor Activity from Hyperinsulinemia.
Andreas Varkaris, Ermira Pazolli, Hakan Gunaydin, Qi Wang, Levi Pierce, D Randal Kipp

Cancer Discov· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Identification of GDC-1971 (RLY-1971), a SHP2 Inhibitor Designed for the Treatment of Solid Tumors.
Alexander M Taylor, Bret R Williams, Fabrizio Giordanetto, Elizabeth H Kelley, André Lescarbeau, D Randal Kipp

J Med Chem· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The path to approval for oral hypomethylating agents in acute myeloid leukemia and myelodysplastic syndromes.
David Kipp, Andrew H Wei

Future Oncol· July 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis